相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of pravastatin on the development of diabetes and adiponectin production
Toshiyuki Takagi et al.
ATHEROSCLEROSIS (2008)
Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice
Sean Morony et al.
CIRCULATION (2008)
Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes
Torbjorn Omland et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria
Birgitte Nellemann et al.
DIABETES CARE (2007)
Osteoprotegerin:: A novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients
Antoine Avignon et al.
DIABETES CARE (2007)
Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome
Sridevi Devaraj et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease
Seigo Sugiyama et al.
ATHEROSCLEROSIS (2007)
Relation of osteoprotegerin to coronary calcium and aortic plaque (from The Dallas Heart Study)
Moeen Abedin et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Drug Insight: statins for nonischemic heart failure - Evidence and potential mechanisms
Michael J. Lipinski et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2007)
Statins in the treatment of chronic heart failure:: Biological and clinical considerations
Pim van der Harst et al.
CARDIOVASCULAR RESEARCH (2006)
The effect of 6 months of treatment with pravastatin on serum adiponectin concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: A pilot study
Kenji Sakamoto et al.
CLINICAL THERAPEUTICS (2006)
Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE(-/-) mice
Brian J. Bennett et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial
Haruo Nakamura et al.
LANCET (2006)
Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients
A Avignon et al.
DIABETES CARE (2005)
Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein
EJ Rhee et al.
CLINICAL SCIENCE (2005)
Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin
P Collin-Osdoby
CIRCULATION RESEARCH (2004)
Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction
T Ueland et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease
S Kiechl et al.
CIRCULATION (2004)
The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis
K Nitta et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2003)
Increased osteoprotegerin serum levels in men with coronary artery disease
M Schoppet et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease
S Jono et al.
CIRCULATION (2002)
Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure
JJ Kazama et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2002)
Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D
PA Price et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2001)
Statins: Effective antiatherosclerotic therapy
RS Blumenthal
AMERICAN HEART JOURNAL (2000)
分享论文
